These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 9805587)

  • 21. Characteristics of internalizing and externalizing disorders in medication-naive, clinically referred children with attention deficit hyperactivity disorder, combined type and dysthymic disorder.
    Sanders M; Arduca Y; Karamitsios M; Boots M; Vance A
    Aust N Z J Psychiatry; 2005 May; 39(5):359-65. PubMed ID: 15860023
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Attention-deficit/hyperactivity disorder.
    Shaywitz BA; Fletcher JM; Shaywitz SE
    Adv Pediatr; 1997; 44():331-67. PubMed ID: 9265975
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sleep disturbances associated with attention deficit hyperactivity disorder: the impact of psychiatric comorbidity and pharmacotherapy.
    Mick E; Biederman J; Jetton J; Faraone SV
    J Child Adolesc Psychopharmacol; 2000; 10(3):223-31. PubMed ID: 11052412
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Attention deficit hyperactivity disorder, combined type, dysthymic disorder and anxiety disorders: differential patterns of neurodevelopmental deficits.
    Vance A; Arduca Y; Sanders M; Karamitsios M; Hall N; Hetrick S
    Psychiatry Res; 2006 Aug; 143(2-3):213-22. PubMed ID: 16876876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit/hyperactivity disorder.
    Bond DJ; Hadjipavlou G; Lam RW; McIntyre RS; Beaulieu S; Schaffer A; Weiss M;
    Ann Clin Psychiatry; 2012 Feb; 24(1):23-37. PubMed ID: 22303520
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Review of attention-deficit/hyperactivity disorder comorbid with oppositional defiant disorder.
    Hazell P
    Australas Psychiatry; 2010 Dec; 18(6):556-9. PubMed ID: 21117844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Integrated pharmacologic treatment of attention-deficit hyperactivity disorder (ADHD).
    Horst RO; Hendren RL
    Essent Psychopharmacol; 2005; 6(5):250-61. PubMed ID: 16222910
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of sleep medication in children with ADHD.
    Efron D; Lycett K; Sciberras E
    Sleep Med; 2014 Apr; 15(4):472-5. PubMed ID: 24684977
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacotherapy of adolescent attention deficit hyperactivity disorder: challenges, choices and caveats.
    Garland EJ
    J Psychopharmacol; 1998; 12(4):385-95. PubMed ID: 10065914
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Attention-deficit/hyperactivity disorder: etiology and pharmacotherapy.
    Noorbala AA; Akhondzadeh S
    Arch Iran Med; 2006 Oct; 9(4):374-80. PubMed ID: 17061613
    [TBL] [Abstract][Full Text] [Related]  

  • 31. When does it end? Attention-deficit/hyperactivity disorder in the middle aged and older populations.
    Manor I; Rozen S; Zemishlani Z; Weizman A; Zalsman G
    Clin Neuropharmacol; 2011; 34(4):148-54. PubMed ID: 21738027
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Attention-deficit/hyperactivity disorder, predominantly inattentive subtype.
    Carlson CL; Mann M
    Child Adolesc Psychiatr Clin N Am; 2000 Jul; 9(3):499-510, vi. PubMed ID: 10944653
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The relationship between tourette syndrome, attention deficit hyperactivity disorder, and stimulant medication: a critical review.
    Erenberg G
    Semin Pediatr Neurol; 2005 Dec; 12(4):217-21. PubMed ID: 16780292
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factors associated with atomoxetine efficacy for treatment of attention-deficit/hyperactivity disorder in children and adolescents.
    Scott NG; Ripperger-Suhler J; Rajab MH; Kjar D
    J Child Adolesc Psychopharmacol; 2010 Jun; 20(3):197-203. PubMed ID: 20578932
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Behavioral parent training as an adjunct to routine care in children with attention-deficit/hyperactivity disorder: moderators of treatment response.
    van den Hoofdakker BJ; Nauta MH; van der Veen-Mulders L; Sytema S; Emmelkamp PM; Minderaa RB; Hoekstra PJ
    J Pediatr Psychol; 2010 Apr; 35(3):317-26. PubMed ID: 19633060
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Perspectives on attention deficit hyperactivity disorder: executive functions, working memory, and language disabilities.
    Westby C; Watson S
    Semin Speech Lang; 2004 Aug; 25(3):241-54. PubMed ID: 15359368
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Attention deficit hyperactivity disorder. Epidemiologic, pathophysiologic, diagnostic and treatment perspectives.
    Al-Ghamdy YS; Qureshi NA
    Saudi Med J; 2001 Aug; 22(8):666-73. PubMed ID: 11573110
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacotherapy of attention-deficit hyperactivity disorder: common quandaries, dilemmas and challenges.
    Mosheva M; Dar N; Rima Madi L; Weizman A; Gothelf D
    Int Clin Psychopharmacol; 2020 Nov; 35(6):300-304. PubMed ID: 32694317
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Period prevalence of concomitant psychotropic medication usage among children and adolescents with attention-deficit/hyperactivity disorder during 2009.
    Betts KA; Sikirica V; Hodgkins P; Zhou Z; Xie J; DeLeon A; Erder MH; Wu EQ
    J Child Adolesc Psychopharmacol; 2014 Jun; 24(5):260-8. PubMed ID: 24839998
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Attention-deficit hyperactivity disorder and brain-derived neurotrophic factor: a speculative hypothesis.
    Tsai SJ
    Med Hypotheses; 2003 Jun; 60(6):849-51. PubMed ID: 12699711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.